Intratumoral Bacteria Interact with Metabolites and Genetic Alterations in Hepatocellular Carcinoma
Overview
Pharmacology
Authors
Affiliations
Zhang L, Duan X, Zhao Y, Zhang D, Zhang Y Front Immunol. 2025; 16:1526589.
PMID: 39995663 PMC: 11847830. DOI: 10.3389/fimmu.2025.1526589.
Mast cells: key players in digestive system tumors and their interactions with immune cells.
Shu F, Yu J, Liu Y, Wang F, Gou G, Wen M Cell Death Discov. 2025; 11(1):8.
PMID: 39814702 PMC: 11735678. DOI: 10.1038/s41420-024-02258-y.
Antitumor potentials of onco-microbial in Chinese patients with pancreatic cancer.
Gao Y, Zhou D, Lu Y, Yang L, Gong X, Chen M Heliyon. 2024; 10(24):e40890.
PMID: 39720030 PMC: 11665473. DOI: 10.1016/j.heliyon.2024.e40890.
Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis.
Jiang F, Dang Y, Zhang Z, Yan Y, Wang Y, Chen Y mSystems. 2024; 10(1):e0076524.
PMID: 39660866 PMC: 11748501. DOI: 10.1128/msystems.00765-24.
The intrahepatic bacterial metataxonomic signature of patients with hepatocellular carcinoma.
Li J, Zhai X, Chen C, Zhang R, Huang X, Liu Y Sci Rep. 2024; 14(1):29077.
PMID: 39580523 PMC: 11585554. DOI: 10.1038/s41598-024-80246-z.